1. Muralidhar A, Potluri HK, Jaiswal T, McNeel DG. (2023) "Targeted Radiation and Immune Therapies-Advances and Opportunities for the Treatment of Prostate Cancer." Pharmaceutics. (PMID: 36678880; PMCID: PMC9863141)


  1. Potluri HK, Ferreira1 CA, Grudzinski J, Massey C, Aluicio-Sarduy E, Engle JW, Kwon O, Marsh IR, Bednarz BP, Hernandez R, Weichert J, and McNeel DG. (2022) “Anti-tumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors.” J ImmunoTherapy of Cancer (in press). (PMID: 36002185, PMCID: PMC9413196)

  2. Jeon D and McNeel DG. (2022) “Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression.” OncoImmunology 11:2054758. (PMID 35340661, PMCID: PMC8942433)

  3. McNeel DG, Eickhoff JC, Wargowski E, Johnson LE, Kyriakopoulos CE, Emamekhoo H, Lang JM, Brennan MJ, and Liu G. (2022) “Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC).” J ImmunoTherapy of Cancer 10:e004198. (PMID: 35277461, PMCID: PMC8919462)

  4. Terrisse S, Goubet A-G, Ueda K, Thomas AM, Quiniou V, Thelemaque C, Dunsmore G, Clave E, Gamat M, Yonekura S, Ferrere G, Rauber C, Pham HP, Fahrner JE, Pizzato E, Li P, Fidelle M, Mazzenga M, Silva CAC, Durant S, Derosa L, Richard C, Blanchard P, Routy B, Culine S, Opolon P, Drake CG, Silvin A, Toubert A, Segata N, McNeel DG, Fizazi K, Kroemer G, and Zitvogel L. (2022) “Immune system and intestinal microbiota determine efficacy of androgen depletion therapy against prostate cancer.” J ImmunoTherapy of Cancer 10:e004191. (PMID: 35296557, PMCID: PMC8928383)

  5. Potluri HK, Ng TL, Newton MA, and McNeel DG. (2022) “GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant.” Cancer Immunol. Immunoth. (pending). (PMID 35133464, PMCID: PMC9744072)

  6. Rastogi I, Jeon D, Moseman JE, Muralidhar A, Potluri HK, McNeel DG. (2022) "Role of B cells as antigen presenting cells." Front Immunol.;13:954936. (PMID: 36159874; PMCID: PMC9493130)


  1. Carlson PM, Mohan M, Patel RB, Birstler J, Nettenstrom L, Sheerar D, Fox K, Rodriguez M, Hoefges A, Hernandez R, Zahm C, Kim K, McNeel DG, Weichert J, Morris ZS, and Sondel PM. (2021) “Optimizing flow cytometric analysis of immune cells in samples requiring cryopreservation from tumor-bearing mice.” J Immunol 207:720-734. (PMID: 34261667, PMCID: PMC8313010)

  2. Zahm CD, Moseman JE, Delmastro LE, and McNeel DG. (2021) “PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy.” Oncoimmunology (in press). (PMID: 33996265, PMCID: PMC8078506)


  1. Potluri HK, Ng TL, Newton MA, Zhang J, Maher CA, Nelson PS, and McNeel DG. (2020) “Antibody profile of prostate cancer patients reveals differences in antibody signatures among disease stages.” J ImmunoTherapy of Cancer (in press). (PMID: 33335027, PMCID: PMC7745697)

  2. Kyriakopoulos CE, Eickhoff JC, Ferrari AC, Schweizer MT, Wargowski E, Olson BM, and McNeel DG. (2020) “Multicenter phase 1 trial of a DNA vaccine encoding the androgen receptor ligand binding domain (pTVG-AR, MVI-118) in patients with metastatic prostate cancer.” Clin Cancer Res (in press). (PMID: 32513836, PMCID: PMC7541575 )

  3. Gamat-Huber M, Jeon D, Johnson LE, Moseman J, Muralidhar A, Potluri H, Rastogi I, Wargowski E, Zahm CD, and McNeel DG. (2020) “Treatment combinations with DNA vaccines for the treatment of metastatic castration-resistant prostate cancer (mCRPC).” Cancers (in press). (PMID: 33008010, PMCID: PMC7601088)


  1. Zahm CD, Johnson LE, and McNeel DG. (2019) “Increased indoleamine 2,3-dioxygenase activity and expression inprostate cancer following targeted immunotherapy.” Cancer Immunol Immunoth 68:1661 -1669. (PMID: 31606777, PMCID: pending)

  2. McNeel DG, Eickhoff JC, Johnson LE, Roth AR, Perk TG, Fong L, Antonarakis ES, Wargowski E, Jeraj R, and Liu G. (2019) “Randomized phase 2 trial of a DNA vaccine encoding prostatic acidphosphatase (pTVG-HP, MVI-816) in patients with progressive non-metastatic,castration-sensitive prostate cancer.” J Clin Oncol 37:3507-3517. (PMID: 31644357, PMCID: pending)

  3. Scarpelli M, Zahm CD, Perlman S, McNeel DG, Jeraj R, and Liu G. (2019) “FLT PET/CT imaging of metastaticprostate cancer patients treated with pTVG-HP DNA vaccine andpembrolizumab.” Journal ImmunoTherapy of Cancer 7:23. (PMID: 30700328, PMCID: PMC6354338)


  1. Zahm CD, Colluru VT, McIlwain SJ, Ong IM, and McNeel DG. (2018) “TLR stimulation during T-cell activation lowers PD-1expression on CD8+ T cells.” Canc Imm Res 6:1364- 1374. (PMID: 30201735, PMCID: PMC6215515)

  2. McNeel DG, Eickhoff JC, Wargowski E, Zahm CD, Staab MJ, Straus J, and Liu G. (2018) “Concurrent, but not sequential, PD-1blockade with a DNA vaccine elicits anti-tumor responses in patients withmetastatic, castration-resistant prostate cancer.” Oncotarget 9:25586-25596. (PMID: 29876010, PMCID: PMC5986652)

  3. Johnson LE, Brockstedt D, Leong M, Lauer P, Theisen E, Sauer J-D, and McNeel DG. (2018) “Heterologous vaccinationtargeting prostatic acid phosphatase (PAP) using DNA and Listeria vaccineselicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNApriming.” Oncoimmunology 7:e1456603. (PMID: 30221049, PMCID: PMC6136874)

  4. Wargowski E, Johnson LE, Eickhoff JC, Delmastro L, Staab MJ, Liu G, and McNeel DG. (2018) “Prime-boost vaccination targetingprostatic acid phosphatase (PAP) in patients with metastaticcastration-resistant prostate cancer (mCRPC) using sipuleucel-T and a DNAvaccine.” Journal ImmunoTherapy of Cancer 6:21. (PMID: 29534736, PMCID: PMC5850960)

  5. McNeel DG. (2018) “Therapeutic CancerVaccines: How Much Closer Are We?” BioDrugs 32:1-7. (PMID 29285731, PMCID: PMC5815920)


  1. England CG, Jiang D, Ehlerding EB, Rekoske BT, Ellison PA, Hernandez R, Barnhart TE, McNeel DG, Huang P, Cai W. Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):110-120. doi: 10.1007/s00259-017-3803-4. PMID: 28821924

  2. McNeel DG. Therapeutic Cancer Vaccines: How Much Closer Are We? BioDrugs. 2017 Dec 28. doi: 10.1007/s40259-017-0257-y. PMID: 29285731

  3. Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HE, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC, Cheever MA, Streicher H, Creekmore SP, Waldmann TA, Conlon KC. A First-in-Human Phase 1 Study of Subcutaneous Outpatient Recombinant Human IL-15 (rhIL-15) in Adults with Advanced Solid Tumors. Clin Cancer Res. 2017 Dec 4. pii: clincanres.2451.2017. doi: 10.1158/1078-0432.CCR-17-2451. PMID: 29203590

  4. Olson BM, Gamat M, Seliski J, Sawicki T, Jeffery J, Ellis L, Drake CG, Weichert J, McNeel DG. Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells. Cancer Immunol Res. 2017 Dec;5(12):1074-1085. doi: 10.1158/2326-6066.CIR-16-0390. PMID: 29051161

  5. Gamat M, McNeel DG. Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocr Relat Cancer. 2017 Dec;24(12):T297-T310. doi: 10.1530/ERC-17-0145. Review. PMID: 28814451

  6. Zahm CD, Colluru VT, McNeel DG. Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells. Cancer Immunol Res. 2017 Aug;5(8):630-641. doi: 10.1158/2326-6066.CIR-16-0374. PMID: 28634215

  7. Johnson LE, Olson BM, McNeel DG. Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. J Immunother Cancer. 2017 Jul 18;5(1):56. doi: 10.1186/s40425-017-0260-3. PMID: 28716080

  8. Zahm CD, Colluru VT, McNeel DG. DNA vaccines for prostate cancer. Pharmacol Ther. 2017 Jun;174:27-42. doi: 10.1016/j.pharmthera.2017.02.016. Review. PMID: 28185916

  9. Ehlerding EB, England CG, Majewski RL, Valdovinos HF, Jiang D, Liu G, McNeel DG, Nickles RJ, Cai W. ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer. Mol Pharm. 2017 May 1;14(5):1782-1789. doi: 10.1021/acs.molpharmaceut.7b00056. PMID: 28388076

  10. Olson BM, Bradley ES, Sawicki T, Zhong W, Ranheim EA, Bloom JE, Colluru VT, Johnson LE, Rekoske BT, Eickhoff JC, McNeel DG. Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD). Prostate. 2017 May;77(7):812-821. doi: 10.1002/pros.23321. PMID: 28181678

  11. England CG, Ehlerding EB, Hernandez R, Rekoske BT, Graves SA, Sun H, Liu G, McNeel DG, Barnhart TE, Cai W. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. J Nucl Med. 2017 Jan;58(1):162-168. doi: 10.2967/jnumed.116.177857. PMID: 27493273

  12. McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer. 2016 Dec 20;4:92. doi: 10.1186/s40425-016-0198-x. eCollection 2016. PMID: 28031820

  13. Heninger E, Krueger TE, Thiede SM, Sperger JM, Byers BL, Kircher MR, Kosoff D, Yang B, Jarrard DF, McNeel DG, Lang JM. Inducible expression of cancer-testis antigens in human prostate cancer. Oncotarget. 2016 Dec 20;7(51):84359-84374. doi: 10.18632/oncotarget.12711. PMID: 27769045


  1. McNeel DG. TCR diversity - a universal cancer immunotherapy biomarker? J Immunother Cancer. 2016 Nov 15;4:69. PMID: 27879971

  2. Colluru VT, Zahm CD, McNeel DG. Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses. Oncoimmunology. 2016 Sep 2;5(10):e1223002. PMID: 27853647

  3. Colluru VT, McNeel DG. B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines. Oncotarget. 2016 Sep 21. doi: 10.18632/oncotarget.12178. PMID: 27661128

  4. Rekoske BT, McNeel DG. Immunotherapy for prostate cancer: False promises or true hope? Cancer. 2016 Dec 1;122(23):3598-3607. doi: 10.1002/cncr.30250. PMID: 27649312

  5. Rekoske BT, Olson BM, McNeel DG. Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. Oncoimmunology. 2016 Mar 28;5(6):e1165377. doi: 10.1080/2162402X.2016.1165377. PMID: 27471641

  6. Bloom JE, McNeel DG. SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. Oncotarget. 2016 Jun 2. doi: 10.18632/oncotarget.9802. PMID: 27276714

  7. Colluru VT, Johnson LE, Olson BM, McNeel DG. Preclinical and clinical development of DNA vaccines for prostate cancer. Urol Oncol. 2016 Apr;34(4):193-204. doi: 10.1016/j.urolonc.2013.09.014. Review. PMID: 24332642

  8. Bradley ES and McNeel DG. “DNA Vaccines.” Marshall JL ed. Encyclopedia of Cancer Therapeutic Targets. New York: Springer, 2016.


  1. McNeel DG, Chen YH, Gulley JL, Dwyer AJ, Madan RA, Carducci MA, DiPaola RS. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). Hum Vaccin Immunother. 2015;11(10):2469-74. doi: 10.1080/21645515. 2015.1062190. PMID: 26111351

  2. Rekoske BT, Smith HA, Olson BM, Maricque BB, McNeel DG. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer Immunol Res. 2015 Aug;3(8):946-55. doi: 10.1158/2326-6066.CIR-14-0206. Epub 2015 Jun 3. PMID: 26041735


  1. McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, Staab MJ, Liu G, Wilding G, Olson BM. Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. Clin Cancer Res. 2014 Jul 15;20(14):3692-704. doi: 10.1158/1078-0432.

  2. Smith HA, Rekoske BT, McNeel DG. DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses. Vaccine. 2014 Mar 26;32(15):1707-15. doi: 10.1016/j.vaccine.2014.01.048.


  1. Olson BM, McNeel DG. Monitoring regulatory immune responses in tumor immunotherapy clinical trials. Front Oncol. 2013 May 6;3:109. doi: 10.3389/fonc.2013.00109.

  2. Lang JM, Wallace M, Becker JT, Eickhoff JC, Buehring B, Binkley N, Staab MJ, Wilding G, Liu G, Malkovsky M, McNeel DG. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.Clin Genitourin Cancer. 2013 Dec;11(4):407-15. doi: 10.1016/j.clgc.2013.04.029.

  3. Johnson LE, Becker JT, Dubovsky JA, Olson BM, McNeel DG. Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments. Chin Clin Oncol. 2013 Mar 1;2(1). doi: 10.3978/j.issn.2304-3865.2012.11.06.

  4. Becker JT, McNeel DG. Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination. J Immunother Cancer. 2013 May 29;1:2. doi: 10.1186/2051-1426-1-2.

  5. Casavant BP, Mosher R, Warrick JW, Maccoux LJ, Berry SM, Becker JT, Chen V, Lang JM, McNeel DG, Beebe DJ. A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells. Methods. 2013 Dec 1;64(2):137-43. doi: 10.1016/j.ymeth.2013.05.027.

  6. Olson BM, Johnson LE, McNeel DG. The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. Cancer Immunol Immunother. 2013 Mar;62(3):585-96. doi: 10.1007/s00262-012-1363-9.


  1. Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ, McNeel DG.Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol. 2012 Dec 15;189(12):5590-601. doi: 10.4049/jimmunol.1201744

  2. Bloom JE, McNeel DG, and Olson BM. Vaccination using peptides spanning the SYT-SSX tumor-specific translocation.. Expert Rev Vaccines. 2012 Dec;11(12):1401-4. doi: 10.1586/erv.12.122.

  3. Johnson LE, Frye TP, McNeel DG. Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. Oncoimmunology. 2012 Dec 1;1(9):1546-1556.

  4. Olson BM and McNeel DG. Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence. Expert Rev Vaccines. 2012 Nov;11(11):1315-7. doi: 10.1586/erv.12.107.

  5. McNeel DG, Becker JT, Johnson LE, and Olson BM. DNA Vaccines for Prostate Cancer.. Curr Cancer Ther Rev. 2012 Nov 1;8(4):254-263.

  6. Bruce JY, Lang JM, McNeel DG, Liu G. Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol. 2012 Nov;10(11):716-22.

  7. Johnson LE, McNeel DG. Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes. Prostate. 2012 May 15;72(7):730-40

  8. Morse MD, McNeel DG. T cells localized to the androgen-deprived prostate are TH1 and TH17 biased. Prostate. 2012 Aug 1;72(11):1239-47.

  9. McNeel DG, Smith HA, Eickhoff JC, Lang JM, Staab MJ, Wilding G, Liu G. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother. 2012 Jul;61(7):1137-47.


  1. Smith HA and McNeel DG. (2011) "Vaccines targeting the cancer testis antigen SSX-2 elicit HLA-A2 epitope-specific CTL that lyse prostate cancer cells." J Immunotherapy. 21904219.

  2. Smith HA, Cronk RJ, Lang JM, McNeel DG. (2011) "Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer." Cancer Research. 21880588 Highlighted in: Fenner A. Prostate cancer: Targeting SSX cancer-testis antigens for immunotherapy. Nat Rev Urol. 2011 Nov 22;8(12):647.

  3. Olson BM and McNeel DG. (2011) "Sipuleucel-T: immunotherapy for advanced prostate cancer." Open Access Jour Urol. 3:49-60.

  4. Zabransky DJ, Smith HA, Thoburn CJ, Zahurak M, Keizman D, Carducci M, Eisenberger MA, McNeel DG, Drake CG, Antonarakis ES. (2011) "Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer." Prostate. 21748855.

  5. Lang JM, Kaikobad MR, Wallace M, Staab MJ, Horvath DL, Wilding G, Liu G, Eickhoff JC, McNeel DG, Malkovsky M. (2011) "Pilot trial of interleukin-2 and zoledronic acid to augment gamma-delta T cells as treatment for patients with refractory renal cell carcinoma." Cancer Immunol Immunother. 21647691.

  6. Olson BM and McNeel DG. (2011) “CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.” Cancer Immunol. Immunoth. 60:781-792.

  7. Smith HA, Maricque BB, Eberhardt J, Petersen B, Gulley JL, Schlom J, and McNeel DG. (2011) IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy. J Biomed Biotechnol. 2011;2011:454861.

  8. Maricque BB, Eickhoff JC, McNeel DG. (2011) “Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer.Prostate 71:134-146.


  1. Smith HA and McNeel DG. (2010) “The SSX family of cancer-testis antigens as target proteins for tumor therapy.” Clin. Dev. Immunol. 2010:150591.

  2. Alam S and McNeel DG. (2010) “DNA vaccines for the treatment of prostate cancer.” Exp. Rev. Vaccines 9:731-745.

  3. Gao JJ, Maricque BB, Morse MD, Huang W, and McNeel DG. (2010) “Identification of autoantibodies in a patient with testicular cancer and concurrent inflammatory bowel disease.J. Clin. Oncol. 28:e680-683.

  4. Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, and McNeel DG. (2010) “DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.” J Immunotherapy 33:639-647.

  5. Morse MD and McNeel DG. (2010) “Prostate cancer patients treated with androgen deprivation therapy develop persistent changes in adaptive immune responses.Human Immunology 71:496-504.

  6. Olson BM, Frye TP, Johnson LD, Fong L, Knutson KL, Disis ML, and McNeel DG. (2010) “HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.” Cancer Immunol. Immunother. 59:943-953.


  1. Lang JM, Andrei A-C, McNeel DG. (2009) “The prioritization of cancer antigens: Keeping the target in sight.Exp. Rev. Vaccines 8:1657-1661.

  2. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, and Wilding G. (2009) “Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with stage D0 prostate cancer.J. Clin. Oncol. 27:4047-4054.

Comments on McNeel DG (2009) J. Clin. Oncol. 27:4047-4054

a. Drake CG. (2009) “Immunotherapy for prostate cancer: walk, don’t run.” J. Clin. Oncol. 27:4035-4037

b. Smith MR and Kantoff PW. (2010) “Changes in PSA kinetics after DNA vaccine therapy – not so fast!” J. Clin. Oncol. 28:e58

3. Olson BM and McNeel DG. “Methods for constructing and evaluating anti-tumor DNA vaccines.” Walther W, Stein US eds. Methods in Molecular Biology, Gene Therapy of Cancer, vol. 542. Totowa: Humana Press, 2009 p. 211-243.


  1. Ward J and McNeel DG. (2007) “GVAX: An allogeneic, whole-cell, GM-CSF-secreting vaccine for the treatment of prostate cancer.” Exp. Opin. Biol. Ther. 7:1893-1902.

  2. Kipp RT and McNeel DG. (2007) “Immunotherapy of prostate cancer.” Clin. Adv. Hem. Onc. 5:465-479.

  3. McNeel DG. (2007) “Prostate cancer immunotherapy.” Curr. Opin. Urol. 17:175-181.

  4. McNeel DG. (2007) “Cellular immunotherapies for prostate cancer.” Biomed Pharmacother. 61:315-322.

  5. Dubovsky JA and McNeel DG. (2007) “Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor.” Prostate 67:1781-1790.

  6. Olson BM and McNeel DG. (2007) “Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer.” Prostate 67:1729-1739.

  7. Dubovsky JA, Albertini MR and McNeel DG. (2007) “MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis.” J. Immunotherapy 30:675-683.

  8. Johnson LE, Frye TP, Chinnasamy D, Chinnasamy N, and McNeel DG. (2007) “Plasmid DNA vaccine encoding prostatic acid phosphatase (PAP) effective in eliciting autologous antigen-specific CD8 T cells.” Cancer Immunol Immunother 56:885-895.


  1. Dunphy EJ, Johnson LE, Olson BM, Frye TP, and McNeel DG. (2006) “New approaches to identification of antigenic candidates for future prostate cancer immunotherapy.” Update on Cancer Therapeutics 22:273-284.

  2. Hoeppner LH, Dubovsky JA, Dunphy EJ, and McNeel DG. (2006) “Humoral immune responses to testis antigens in sera from patients with prostate cancer.” Cancer Immun. [serial online] 6:1-7.

  3. Mooney CJ, Dunphy EJ, Stone B, and McNeel DG. (2006) “Identification of autoantibodies elicited in a patient with prostate cancer presenting as dermatomyositis” Int. J. Urol. 13:211-217.

  4. Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, and McNeel DG. (2006) “Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).” Vaccine 24:293-303.


  1. McNeel DG and Malkovsky M. (2005) “Immune-based therapies for prostate cancer.” Immunol. Lett. 96:3-9.

  2. McNeel DG. “Prostate cancer antigens and vaccines, preclinical developments.” In: Giaccone G, Schilsky R, Sondel P. eds. Cancer Chemotherapy and Biological Response Modifiers, Annual 22. Oxford: Elsevier Limited, 2005 p. 247-261.

  3. Dunphy EJ and McNeel DG. (2005) “Antigen-specific IgG elicited in subjects with prostate cancer treated with flt3 ligand.” J. Immunotherapy 28:268-275.


  1. Dunphy EJ, Eickhoff JC, Muller CH, Berger RE, and McNeel DG. (2004) “Identification of antigen-specific IgG in sera from patients with chronic prostatitis.” J. Clin. Immunol. 24:492-502.